arrow
K

Kazushige Wakuda

Shizuoka Cancer Center
H指数:30
被引数:2,552

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tarlatamab in small cell lung cancer following platinum-based chemotherapy: subgroup analysis of Japanese patients from the DeLLphi-304 study

塔拉他马布在铂类化疗后的小细胞肺癌中的应用:DeLLphi-304研究中日本患者的亚组分析

2026-09-190
OAAI
Efficacy of Docetaxel Plus Ramucirumab for Malignant Pleural Effusion and Cerebral Edema in Patients With Advanced Non-Small Cell Lung Cancer: A Single-Institution Retrospective Study

多西他赛联合雷莫芦单抗对晚期非小细胞肺癌患者恶性胸腔积液和脑水肿的疗效:一项单机构回顾性研究

2026-05-010
OAAI
Efficacy of Osimertinib in Patients With Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring Sensitizing EGFR Mutations

奥希替尼对携带敏感EGFR突变且术后复发的非小细胞肺癌患者的疗效

2026-04-240
OAAI
Evaluation of postoperative pain by PainVision® PS-2100, a quantitative analyzer for perception and pain in pulmonary resection: a prospective pilot study

使用PainVision® PS-2100(一种用于肺切除术后痛觉和疼痛感知的定量分析器)评估术后疼痛:一项前瞻性试点研究

2026-04-010
PRE
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing

II期研究:阿法替尼治疗携带罕见表皮生长因子受体突变(包括由下一代测序检测到的复合突变)的晚期非小细胞肺癌

2025-07-060
PRE
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for advanced nonsquamous non-small cell lung cancer with impaired renal function: A multicenter, single-arm phase 2 trial (RESTART, LOGiK 2002)

阿特珠单抗联合卡铂加白蛋白结合型紫杉醇组合疗法治疗肾功能受损的晚期非鳞状非小细胞肺癌:一项多中心、单臂II期试验(RESTART,LOGiK 2002)

2025-05-010
OAAI
A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
2023-12-011
OA
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
2023-10-011
OA
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
2023-09-250
OAAI
Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments

不同抗癌治疗后肺癌患者B7-H3表达的免疫组织化学分析

2023-04-103
PRE
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
2023-03-063
OAAI
Histologic transformation of epidermal growth factor receptor-mutated lung cancer

表皮生长因子受体突变肺癌的组织学转化

2022-05-0115
PRE
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC

Pembrolizumab联合化疗治疗非鳞状NSCLC有效性和安全性的真实世界研究

2022-02-0133
OA
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

EGFR突变的非小细胞肺癌egfr-tki治疗过程中寡残留病与失败模式的关系: 一项回顾性研究

2021-11-194
OAAI
Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer (Oct, 10.1007/s10637-021-01191-6, 2021)

durvalumab治疗局部晚期非小细胞肺癌患者后肺炎的预后影响 (10月,10.1007/s10637-021-01191-6,2021)

2021-11-080
OA
Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

局限型小细胞肺癌患者长期生存资料的回顾性分析

2021-10-307
PRE